Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Academic partnerships signal Propanc Biopharma, Inc. push into aging biology and tumor resistance science
Propanc Biopharma expands Spanish research alliances ahead of first human oncology trials. Discover what this means for PRP development and strategy.
Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?
Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.
Can X4 Pharmaceuticals and Norgine unlock EU access to the first targeted WHIM therapy?
EMA backs mavorixafor for WHIM syndrome. Explore what EU approval could mean for access, evidence standards, and rare immunology treatment.
Scynexis expands SCY-247 program with IV SAD and MAD trial launch
SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.
Biomerica’s responder data raises new questions about diet-driven IBS management
Biomerica reports real-world IBS responder data and Medicare coverage. Explore what this means for adoption, reimbursement, and competition.
Profusa Lumee Oxygen gains pre-approval orders as EU MDR decision looms
Profusa secures Lumee Oxygen orders ahead of EU MDR clearance. Discover what this means for CLTI monitoring and 2026 commercialization.
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.
What Applied Medical Technology’s Explant Express FDA clearance reveals about breast implant explantation workflows
FDA clears Explant Express for ruptured breast implant removal. Explore what this means for surgical workflows, adoption risks, and explantation standardisation.